Base de dados : MEDLINE
Pesquisa : C14.907.355.830.925 [Categoria DeCS]
Referências encontradas : 21553 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2156 ir para página                         

  1 / 21553 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29472180
[Au] Autor:Stubbs MJ; Mouyis M; Thomas M
[Ad] Endereço:University College London Hospital, London, UK m.stubbs@doctors.org.uk.
[Ti] Título:Deep vein thrombosis.
[So] Source:BMJ;360:k351, 2018 02 22.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Perna (Membro)/irrigação sanguínea
Trombose Venosa/diagnóstico
[Mh] Termos MeSH secundário: Anticoagulantes/uso terapêutico
Biomarcadores/análise
Produtos de Degradação da Fibrina e do Fibrinogênio/análise
Seres Humanos
Fatores de Risco
Ultrassonografia
Trombose Venosa/sangue
Trombose Venosa/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 0 (Biomarkers); 0 (Fibrin Fibrinogen Degradation Products); 0 (fibrin fragment D)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180224
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k351


  2 / 21553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214793
[Au] Autor:Yoon JK; Kim MD; Lee DY; Han SJ
[Ad] Endereço:Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea.
[Ti] Título:Mesocaval Shunt Creation for Jejunal Variceal Bleeding with Chronic Portal Vein Thrombosis.
[So] Source:Yonsei Med J;59(1):162-166, 2018 Jan.
[Is] ISSN:1976-2437
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:The creation of transjugular intrahepatic portosystemic shunt (TIPS) is a widely performed technique to relieve portal hypertension, and to manage recurrent variceal bleeding and refractory ascites in patients where medical and/or endoscopic treatments have failed. However, portosystemic shunt creation can be challenging in the presence of chronic portal vein occlusion. In this case report, we describe a minimally invasive endovascular mesocaval shunt creation with transsplenic approach for the management of recurrent variceal bleeding in a portal hypertension patient with intra- and extrahepatic portal vein occlusion.
[Mh] Termos MeSH primário: Varizes Esofágicas e Gástricas/complicações
Varizes Esofágicas e Gástricas/terapia
Hemorragia Gastrointestinal/complicações
Hemorragia Gastrointestinal/terapia
Jejuno/patologia
Derivação Portocava Cirúrgica
Veia Porta/patologia
Trombose Venosa/complicações
Trombose Venosa/terapia
[Mh] Termos MeSH secundário: Adolescente
Doença Crônica
Varizes Esofágicas e Gástricas/diagnóstico por imagem
Feminino
Hemorragia Gastrointestinal/diagnóstico por imagem
Seres Humanos
Veia Porta/diagnóstico por imagem
Veia Porta/cirurgia
Tomografia Computadorizada por Raios X
Resultado do Tratamento
Trombose Venosa/diagnóstico por imagem
[Pt] Tipo de publicação:CASE REPORTS
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2018.59.1.162


  3 / 21553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778440
[Au] Autor:De Gottardi A; Trebicka J; Klinger C; Plessier A; Seijo S; Terziroli B; Magenta L; Semela D; Buscarini E; Langlet P; Görtzen J; Puente A; Müllhaupt B; Navascuès C; Nery F; Deltenre P; Turon F; Engelmann C; Arya R; Caca K; Peck-Radosavljevic M; Leebeek FWG; Valla D; Garcia-Pagan JC; VALDIG Investigators
[Ad] Endereço:Hepatology, Department of Clinical Research and Clinic of Visceral Surgery and Medicine, Inselspital, University of Berne, Berne, Switzerland.
[Ti] Título:Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.
[So] Source:Liver Int;37(5):694-699, 2017 May.
[Is] ISSN:1478-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Direct-acting oral anticoagulants (DOACs) are used in patients with splanchnic vein thrombosis (SVT) and cirrhosis, but evidence for safety and efficacy in this setting is limited. Our aim was to identify indications and reasons for starting or switching to DOACs and to report adverse effects, complications and short-term outcome. METHODS: Data collection including demographic information, laboratory values, treatment and complications through the Vascular Liver Disease Interest Group Consortium. RESULTS: Forty-five centres (90%) of the consortium completed the initial eCRF. We report here a series of 94 patients from 17 centres. Thirty-six patients (38%) had cirrhosis. Child-Pugh score was 6 (range 5-8), and MELD score 10.2 (range 6-19). Indications for anticoagulation were splanchnic vein thrombosis (75%), deep vein thrombosis (5%), atrial fibrillation (14%) and others (6%). DOACs used were rivaroxaban (83%), dabigatran (11%) and apixaban (6%). Patients were followed up for a median duration of 15 months (cirrhotic) and 26.5 months (non-cirrhotic). Adverse events occurred in 17% of patients and included one case of recurrent portal vein thrombosis and five cases of bleeding. Treatment with DOACs was stopped in three cases. The major reasons for choosing DOACs were no need for monitoring or inadequacy of INR to guide anticoagulation in cirrhotic patients. Renal and liver function did not change during treatment. CONCLUSIONS: A consistent number of patients with SVT and/or cirrhosis are currently treated with DOACs, which seem to be effective and safe. These data provide a basis for performing randomized clinical trials of DOACs vs. low molecular weight heparin or vitamin K antagonists.
[Mh] Termos MeSH primário: Anticoagulantes/efeitos adversos
Anticoagulantes/uso terapêutico
Fibrilação Atrial/tratamento farmacológico
Cirrose Hepática/complicações
Trombose Venosa/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Oral
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Europa (Continente)
Feminino
Hemorragia Gastrointestinal/induzido quimicamente
Seres Humanos
Masculino
Meia-Idade
Circulação Esplâncnica/fisiologia
Vitamina K/antagonistas & inibidores
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Anticoagulants); 12001-79-5 (Vitamin K)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1111/liv.13285


  4 / 21553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29192092
[Au] Autor:den Heijer M; Bakker A; Gooren L
[Ad] Endereço:Department of internal medicine, VU Medical Center, Amsterdam, Netherlands m.denheijer@vumc.nl.
[Ti] Título:Long term hormonal treatment for transgender people.
[So] Source:BMJ;359:j5027, 2017 11 30.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Terapia de Reposição Hormonal/efeitos adversos
Terapia de Reposição Hormonal/utilização
Policitemia/induzido quimicamente
Pessoas Transgênero/psicologia
Trombose Venosa/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Assistência ao Convalescente
Idoso
Antagonistas de Androgênios/farmacologia
Estrogênios/administração & dosagem
Estrogênios/farmacologia
Feminino
Disforia de Gênero/psicologia
Guias como Assunto
Seres Humanos
Masculino
Policitemia/complicações
Fatores de Risco
Testosterona/administração & dosagem
Testosterona/farmacologia
Tempo
Trombose Venosa/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Estrogens); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5027


  5 / 21553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465588
[Au] Autor:Ammann EM; Cuker A; Carnahan RM; Perepu US; Winiecki SK; Schweizer ML; Leonard CE; Fuller CC; Garcia C; Haskins C; Chrischilles EA
[Ad] Endereço:College of Public Health.
[Ti] Título:Chart validation of inpatient International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) administrative diagnosis codes for venous thromboembolism (VTE) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database.
[So] Source:Medicine (Baltimore);97(8):e9960, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Sentinel Distributed Database (SDD) is a database of patient administrative healthcare records, derived from insurance claims and electronic health records, sponsored by the US Food and Drug Administration for evaluation of medical product outcomes. There is limited information on the validity of diagnosis codes for acute venous thromboembolism (VTE) in the SDD and administrative healthcare data more generally.In this chart validation study, we report on the positive predictive value (PPV) of inpatient administrative diagnosis codes for acute VTE-pulmonary embolism (PE) or lower-extremity or site-unspecified deep vein thrombosis (DVT)-within the SDD. As part of an assessment of thromboembolic adverse event risk following treatment with intravenous immune globulin (IGIV), charts were obtained for 75 potential VTE cases, abstracted, and physician-adjudicated.VTE status was determined for 62 potential cases. PPVs for lower-extremity DVT and/or PE were 90% (95% CI: 73-98%) for principal-position diagnoses, 80% (95% CI: 28-99%) for secondary diagnoses, and 26% (95% CI: 11-46%) for position-unspecified diagnoses (originating from physician claims associated with an inpatient stay). Average symptom onset was 1.5 days prior to hospital admission (range: 19 days prior to 4 days after admission).PPVs for principal and secondary VTE discharge diagnoses were similar to prior study estimates. Position-unspecified diagnoses were less likely to represent true acute VTE cases.
[Mh] Termos MeSH primário: Bases de Dados Factuais/normas
Imunoglobulinas Intravenosas/efeitos adversos
Classificação Internacional de Doenças/normas
Registros Médicos/normas
Tromboembolia Venosa/diagnóstico
[Mh] Termos MeSH secundário: Registros Eletrônicos de Saúde
Feminino
Hospitalização/estatística & dados numéricos
Seres Humanos
Masculino
Meia-Idade
Valor Preditivo dos Testes
Embolia Pulmonar/induzido quimicamente
Embolia Pulmonar/diagnóstico
Reprodutibilidade dos Testes
Medição de Risco/normas
Medição de Risco/estatística & dados numéricos
Estados Unidos
Tromboembolia Venosa/induzido quimicamente
Trombose Venosa/induzido quimicamente
Trombose Venosa/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Immunoglobulins, Intravenous)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009960


  6 / 21553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29207378
[Au] Autor:Akkiz H; Carr BI; Yalçin K K; Guerra V; Kuran S; Altintas E; Üsküdar O; Karaogullarindan Ü; Özakyol A; Tokmak S; Yücesoy M; Bahçeci HI; Ülkü A; Akçam T; Yalçin Polat K; Ekinci N; Simsek H; Örmeci N; Sonsuz A; Demir M; Kiliç M; Uygun A; Balli T; Demir A; Arslan B; Doran F
[Ad] Endereço:Gastroenterology Department, Çukurova Üniversitesi, Adana, Turkey.
[Ti] Título:Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients.
[So] Source:Oncology;94(2):116-124, 2018.
[Is] ISSN:1423-0232
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:A large cohort of hepatocellular carcinoma (HCC) patients from several collaborating Turkish institutions were examined for the tumor parameters of maximum diameter (MTD), portal vein thrombosis (PVT), and α-fetoprotein (AFP) levels. A relationship was found between MTD and blood platelet levels. Patients with large ≥5 cm tumors who had normal platelet levels had significantly larger tumors, higher percent of PVT, and significantly lower blood total bilirubin and liver cirrhosis than similar ≥5 cm tumor patients having thrombocytopenia. A comparison of patients with and without PVT showed significantly larger tumors, greater multifocality, blood AFP, and C-reactive protein levels, and, interestingly, lower HDL levels in the patients with PVT. Fifty-eight percent of the total cohort had AFP levels ≤100 IU/mL (and 42.1% had values ≤20 IU/mL). These patients had significantly smaller tumors, less tumor multifocality and percent PVT, lower total bilirubin, and less cirrhosis. There was considerable geographic heterogeneity within Turkey in the patterns of HCC presentation, with areas of higher and lower hepatitis B virus, hepatitis D virus, cirrhosis, and tumor aggressiveness parameters. Turkish patients thus have distinct patterns of presentation, but the biological relationships between MTD and both platelets and bilirubin levels are similar to the relationships that have been reported in other ethnic patient groups.
[Mh] Termos MeSH primário: Carcinoma Hepatocelular/patologia
Neoplasias Hepáticas/patologia
[Mh] Termos MeSH secundário: Bilirrubina/sangue
Biomarcadores Tumorais/sangue
Plaquetas/patologia
Proteína C-Reativa/metabolismo
Carcinoma Hepatocelular/sangue
Carcinoma Hepatocelular/metabolismo
Feminino
Seres Humanos
Cirrose Hepática/sangue
Cirrose Hepática/metabolismo
Cirrose Hepática/patologia
Testes de Função Hepática/métodos
Neoplasias Hepáticas/sangue
Neoplasias Hepáticas/metabolismo
Masculino
Meia-Idade
Veia Porta/patologia
Prognóstico
Estudos Prospectivos
Trombocitopenia/sangue
Trombocitopenia/metabolismo
Trombocitopenia/patologia
Turquia
Trombose Venosa/sangue
Trombose Venosa/metabolismo
Trombose Venosa/patologia
alfa-Fetoproteínas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (alpha-Fetoproteins); 9007-41-4 (C-Reactive Protein); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1159/000484564


  7 / 21553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390402
[Au] Autor:Jiang Z; Ma J; Wang Q; Wu F; Ping J; Ming L
[Ad] Endereço:Department of Clinical Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
[Ti] Título:Circulating microRNA expression and their target genes in deep vein thrombosis: A systematic review and bioinformatics analysis.
[So] Source:Medicine (Baltimore);96(50):e9330, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Clinically, D-dimer is the only established biomarker for the diagnosis of deep vein thrombosis (DVT). However, low specificity discounts its diagnostic value. Several publications have illustrated the differentially expressed circulating microRNAs (miRNAs) and their potential diagnostic values for DVT patients. Therefore, we systematically evaluated present researches and further performed bioinformatics analysis, to provide new insights into the diagnosis and underlying mechanisms of miRNAs in DVT. METHODS: Databases PubMed, Web of Science, and Embase were searched from January 2000 to April 2017. Articles on circulating miRNAs expression in DVT were retrieved and reference lists were handpicked. Bioinformatics analysis was conducted for further evaluation. RESULTS: Eventually, the eligibility criteria for inclusion in this study were met by 3 articles, which consisted of 13 specially expressed miRNAs and 149 putative target genes. Two representative KEGG pathways, vascular endothelial growth factor and phosphatidylinositol 3'-kinase (PI3K)-Akt signaling pathway, seemed to participate in the regulatory network of thrombosis. CONCLUSIONS: Despite the potential diagnostic value and regulation effect, the results of circulating miRNAs used as biomarkers for DVT are not so encouraging. More in-depth and larger sample investigations are needed to explore the diagnostic and therapeutic values of miRNAs for DVT.
[Mh] Termos MeSH primário: MicroRNA Circulante/genética
Trombose Venosa/genética
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Biologia Computacional
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Circulating MicroRNA)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009330


  8 / 21553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29315455
[Au] Autor:Othieno R; Okpo E; Forster R
[Ad] Endereço:NHS Lothian, Directorate of Public Health and Health Policy, Waverly Gate, 2-4 Waterloo Place, Edinburgh, UK, EH1 3EG.
[Ti] Título:Home versus in-patient treatment for deep vein thrombosis.
[So] Source:Cochrane Database Syst Rev;1:CD003076, 2018 01 09.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Deep vein thrombosis (DVT) occurs when a blood clot blocks blood flow through a vein, which can occur after surgery, after trauma, or when a person has been immobile for a long time. Clots can dislodge and block blood flow to the lungs (pulmonary embolism (PE)), causing death. DVT and PE are known by the term venous thromboembolism (VTE). Heparin (in the form of unfractionated heparin (UFH)) is a blood-thinning drug used during the first three to five days of DVT treatment. Low molecular weight heparins (LMWHs) allow people with DVT to receive their initial treatment at home instead of in hospital. This is an update of a review first published in 2001 and updated in 2007. OBJECTIVES: To compare the incidence and complications of venous thromboembolism (VTE) in patients treated at home versus patients treated with standard in-patient hospital regimens. Secondary objectives included assessment of patient satisfaction and cost-effectiveness of treatment. SEARCH METHODS: For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register (last searched 16 March 2017), the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2), and trials registries. We also checked the reference lists of relevant publications. SELECTION CRITERIA: Randomised controlled trials (RCTs) examining home versus hospital treatment for DVT, in which DVT was clinically confirmed and was treated with LMWHs or UFH. DATA COLLECTION AND ANALYSIS: One review author selected material for inclusion, and another reviewed the selection of trials. Two review authors independently extracted data and assessed included studies for risk of bias. Primary outcomes included combined VTE events (PE and recurrent DVT), gangrene, heparin complications, and death. Secondary outcomes were patient satisfaction and cost implications. We performed meta-analysis using fixed-effect models with risk ratios (RRs) and 95% confidence intervals (CIs) for dichotomous data. MAIN RESULTS: We included in this review seven RCTs involving 1839 randomised participants with comparable treatment arms. All seven had fundamental problems including high exclusion rates, partial hospital treatment of many in the home treatment arms, and comparison of UFH in hospital versus LMWH at home. These trials showed that patients treated at home with LMWH were less likely to have recurrence of VTE events than those given hospital treatment with UFH or LMWH (fixed-effect risk ratio (RR) 0.58, 95% confidence interval (CI) 0.39 to 0.86; 6 studies; 1708 participants; P = 0.007; low-quality evidence). No clear difference was seen between groups for major bleeding (RR 0.67, 95% CI 0.33 to 1.36; 6 studies; 1708 participants; P = 0.27; low-quality evidence), minor bleeding (RR 1.29, 95% CI 0.94 to 1.78; 6 studies; 1708 participants; P = 0.11; low-quality evidence), or mortality (RR 0.69, 95% CI 0.44 to 1.09; 6 studies; 1708 participants; P = 0.11; low-quality evidence). The included studies reported no cases of venous gangrene. We could not combine patient satisfaction and quality of life outcomes in meta-analysis owing to heterogeneity of reporting, but two of three studies found evidence that home treatment led to greater improvement in quality of life compared with in-patient treatment at some point during follow-up, and the third study reported that a large number of participants chose to switch from in-patient care to home-based care for social and personal reasons, suggesting it is the patient's preferred option (very low-quality evidence). None of the studies included in this review carried out a full cost-effectiveness analysis. However, a small randomised economic evaluation of the two alternative treatment settings involving 131 participants found that direct costs were higher for those in the in-patient group. These findings were supported by three other studies that reported on their costs (very low-quality evidence).Quality of evidence for data from meta-analyses was low to very low. This was due to risk of bias, as many of the included studies used unclear randomisation techniques, and blinding was a concern for many. Also, indirectness was a concern, as most studies included a large number of participants randomised to the home (LMWH) treatment group who were treated in hospital for some or all of the treatment period. A further issue for some outcomes was heterogeneity that was evident in measurement and reporting of outcomes. AUTHORS' CONCLUSIONS: Low-quality evidence suggests that patients treated at home with LMWH are less likely to have recurrence of VTE than those treated in hospital. However, data show no clear differences in major or minor bleeding, nor in mortality (low-quality evidence), indicating that home treatment is no worse than in-patient treatment for these outcomes. Because most healthcare systems are moving towards more LMWH usage in the home setting it is unlikely that additional large trials will be undertaken to compare these treatments. Therefore, home treatment is likely to become the norm, and further research will be directed towards resolving practical issues by devising local guidelines that include clinical prediction rules, developing biomarkers and imaging that can be used to tailor therapy to disease severity, and providing training for community healthcare workers who administer treatment and monitor treatment progress.
[Mh] Termos MeSH primário: Fibrinolíticos/uso terapêutico
Heparina/uso terapêutico
Serviços de Assistência Domiciliar
Hospitalização
Trombose Venosa/tratamento farmacológico
[Mh] Termos MeSH secundário: Análise Custo-Benefício
Hemorragia/induzido quimicamente
Heparina/efeitos adversos
Heparina de Baixo Peso Molecular/efeitos adversos
Heparina de Baixo Peso Molecular/uso terapêutico
Seres Humanos
Ensaios Clínicos Controlados Aleatórios como Assunto
Recidiva
Prevenção Secundária
Terapia Trombolítica/normas
Trombose Venosa/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Fibrinolytic Agents); 0 (Heparin, Low-Molecular-Weight); 9005-49-6 (Heparin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD003076.pub3


  9 / 21553 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29466152
[Au] Autor:Garcia D
[Ad] Endereço:From the Department of Medicine, University of Washington, Seattle.
[Ti] Título:Hybrid Strategy to Prevent Venous Thromboembolism after Joint Arthroplasty.
[So] Source:N Engl J Med;378(8):762-763, 2018 02 22.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Artroplastia do Joelho
Tromboembolia Venosa
[Mh] Termos MeSH secundário: Anticoagulantes
Artroplastia de Quadril
Seres Humanos
Complicações Pós-Operatórias
Trombose Venosa
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Nm] Nome de substância:
0 (Anticoagulants)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMe1716534


  10 / 21553 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443665
[Au] Autor:Lai HT; Huang SH
[Ad] Endereço:Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
[Ti] Título:Phlegmasia Cerulea Dolens with Compartment Syndrome.
[So] Source:N Engl J Med;378(7):658, 2018 Feb 15.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndromes Compartimentais/etiologia
Trombose Venosa/complicações
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Veia Femoral
Seres Humanos
Veia Ilíaca
Masculino
Veia Cava Inferior
Trombose Venosa/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMicm1704996



página 1 de 2156 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde